Sanofi Says Notus Phase 3 Trial of Dupixent Met Primary Endpoint
27 11월 2023 - 4:40PM
Dow Jones News
By Pierre Bertrand
Sanofi said a second phase three trial of Dupixent met its
primary endpoint with what the company said was overwhelming
efficacy.
Sanofi said that its Notus trial confirmed positive published
results from the Phase 3 Boreas trial.
The Notus trial found that the treatment "significantly reduced
exacerbations" and that treatment with Dupixent led to rapid and
significant improvements in lung function for patients with the
life-threatening respiratory disease, COPD.
"These results were from an interim analysis and, given the
overwhelming positive efficacy of the primary endpoint, will be
considered the primary analysis of the trial," Sanofi said.
It added that it and Regeneron plan to submit these latest
findings, in addition to the data from the Boreas trial, to the
U.S. Food and Drug Administration by the end of the year.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
November 27, 2023 02:25 ET (07:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sanofi (NASDAQ:SNY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024